Skip to main content
OpenTrials
Completed

NCT Number: NCT01711294

Evaluation of PCLs Using Three EUS-FNA Needles

To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Changhai Hospital, Shanghai, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pancreatic cystic lesion measuring 13mm or greater in largest diameter.
  • Indicated for EUS evaluation of the PCL including EUS-FNA.
  • Age 18 years of age or older.
  • Willing and able to comply with the study procedures and provide written informed consent form to participate in the study.

Exclusion criteria

  • Cysts in which FNA is not indicated based on review by the clinician, including potential concern of blood vessel location relative to the cyst.
  • Requirement for anticoagulation using clopidogril, warfarin, or other long acting antiplatelet agents (with the exception of aspirin) that cannot be safely stopped according to institutional guidelines.
  • Standard contraindications for EUS.
  • Known pancreatic pseudocyst.
  • Pregnancy.

Treatment and study plan

19 G Flex Needle

Device

Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.

22 G Needle

Device

Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

19 G Needle

Device

Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

Primary outcomes

  1. Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume

    Time frame: At procedure (Up to 1 hour)

    Volume of aspirated cyst fluid as a function of estimated maximal volume, based on pre-aspiration EUS measure of cyst diameter (s) (% aspiration of total estimated volume)

Secondary outcomes

  1. Number of Patients With Related Adverse Events

    Time frame: 30 days

    Adverse events related to study procedure or study device were tabulated. Adverse events were assessed from the index procedure up to 30 days post procedure.

  2. Change in Volume of Cyst Post Initial Procedure Compared to Pre Procedure

    Time frame: Procedure (Up to 1 hour)

    Change value is calculated as cyst volume measured after initial procedure (up to 1 hour) minus volume measured at the beginning of the initial procedure. Volume is measured using the standard geometric formula 4/3 πr³ where r is half the long axis. The volume unit is cc.

  3. Number of Participants With Successful Echoendoscopic Fine Needle Aspiration of PCL

    Time frame: Procedure (up to 1 hour)

    Successful echoendoscopic fine needle aspiration of PCL, defined as complete cyst aspiration (final cyst maximal diameter of less than 5mm) or collection of aspirate adequate to perform two standard assays: cytology and carcinoembryonic antigen (CEA) (sample volume of 3 cc or more)

  4. Number of Participants With PCL Reached/Penetrated

    Time frame: Procedure (Up to 1 hour)

    Patients whose pancreatic cyst lesion(s) can be reached and penetrated by the EUS-FNA needles.

  5. Number of EUS-FNA Needle Passes at Initial Procedure.

    Time frame: Procedure (Up to 1 hour)

    Needle pass defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst.

  6. Number of EUS-FNA Needles Used at Initial Procedure.

    Time frame: Procedure (Up to 1 hour)

    Total number of EUS-FNA needles used across all participants at the initial procedure.

  7. Time Needed for Aspiration for Each Needle Pass at Initial Procedure.

    Time frame: Procedure (Up to 1 hour)

    Needle pass is defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst.

    Time of needle pass in is time of the first needle puncture into the cyst lumen. Needle pass out is time of removal of needle outside the cyst lumen, or after 10 seconds of failed attempt to aspirate fluid after the last needle re-repositioning in a single or multi-compartment cyst.

  8. Time From First Needle Pass in to Last Needle Pass Out at Initial Procedure.

    Time frame: Procedure (Up to 1 hour)

    Needle pass is defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst. Time of first needle pass in is time of the first needle puncture into the cyst lumen. Time of last needle pass out is time of removal of needle outside the cyst lumen at the end of the last fluid aspiration from a single or multi-loculated cyst, or after 10 seconds of failed attempt to aspirate fluid after the last needle re-repositioning in a single or multi-compartment cyst.

  9. Number of Needles With Needle Insertion Rated as Excellent/Very Good

    Time frame: Procedure (Up to 1 hour)

    Number of needles rated either Excellent or Very good when inserted into the echoendoscope at the initial procedure.

  10. Number of Needles With Needle Removal Rated as Excellent/Very Good

    Time frame: Procedure (Up to 1 hour)

    Number of needles rated either Excellent or Very good when removed from the echoendoscope at the initial procedure.

  11. Number of Needles With Needle Visualization Rated as Excellent/Very Good

    Time frame: Procedure (Up to 1 hour)

    Number of needles rated either Excellent or Very good for visualization at the initial procedure.

  12. Number of Participants With Accurate Diagnosis of the Disease State Using the EUS-FNA Needles

    Time frame: up to 2 years

    In order to assess the accuracy of EUS-FNA-based standard assays (cytology and CEA) as a diagnostic measure of disease state, the Disease State per EUS-FNA measure was compared to a reference diagnosis. The reference diagnostic standard was diagnosis from a surgical specimen histology, the true gold standard for cases that evolved to surgical resection within the follow-up of the study. For cases that did not progress to surgery within the follow-up period, the reference diagnostic standard was a composite diagnosis by a consensus board. The consensus board consisted of 3 experts who were blinded to the type of needle used. The consensus board diagnoses of disease state were based on baseline medical history, EUS and cross sectional imaging of the cyst, and aspirate characteristics (i.e. aspirate color and viscosity). If the EUS-FNA diagnosis matches with the histopathology or consensus board diagnosis, then the participant will be counted as having accurate diagnosis.

  13. Number of Participants Requiring Post EUS-FNA Patient Management

    Time frame: 30 days

    Post EUS-FNA patient management required (clinical and/or imaging surveillance, percutaneous drainage, surgical removal).

  14. Number of Participants Whose Management Decision Was Directly Influenced by the EUS Findings

    Time frame: Procedure - 30 days after procedure

    Patients whose Post EUS-FNA Management (clinical and/or imaging surveillance, percutaneous drainage, surgical removal) was Directly Influenced by the EUS-FNA findings.

  15. Rate of Cross-over to Salvage Arm

    Time frame: Procedure (Immediate)

    In the case of inability to access the pancreatic cystic lesion or to attain complete cyst aspiration, salvage aspiration procedure should be performed. Patients randomized to 19G Flex should undergo a salvage procedure with 22G or 19G needle (needle choice at discretion of physician); patients randomized to 22G or 19G should undergo salvage procedure with 19G Flex needle.

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

A Multicenter, Prospective, Randomized Study on Endosonographic Evaluation of Pancreatic Cystic Lesions Using 22 G, 19 G, and Flexible 19 G Fine Needle Aspiration

Important dates

Study start
2013
Primary completion
2017
Study completion
2019
First posted
Oct 22, 2012
Registry last updated
Jan 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.